Elusys Awarded Additional $16 Million To Complete Development of Lyophilized Form of Anthim

PINE BROOK, New Jersey—Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded $16 million of additional funding from the U.S. Government to further advance…  

Oct 06 2015

FDA Accepts NDA for Abilify with Ingestible Sensor

—Amanda Pedersen, Senior Staff Writer, Medical Device Daily, September 15th, 2015

Digital technology has advanced to the point of allowing pharmaceutical companies to make drugs…  

Sep 15 2015

Catalyst Biosciences Completes Merger with Targacept

SOUTH SAN FRANCISCO, California—(GLOBE NEWSWIRE)—Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today…  

Aug 20 2015

Entellus Medical Announces Collaboration with Fiagon

PLYMOUTH, Minnesota—Entellus Medical, Inc. (“Entellus Medical” or the “Company”) (NASDAQ: ENTL), a medical technology company focused on the design, development and commercialization of products for…  

Aug 10 2015

Entellus Medical Announces Positive 24 Month Data from Remodel Trial, Meta-Analysis Across 6 Studies

PLYMOUTH, Minnesota—Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in…  

Jul 31 2015

Allergan Strengthens DARPin Development and Discovery Alliance with Molecular Partners

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (ticker: MOLN) today announced that Allergan, Inc. has reinforced its broad commitment to the discovery, research and development of multiple DARPin‐based…  

Jul 21 2015

Catalyst Biosciences Announces Positive Results From a Phase I Clinical Trial

SOUTH SAN FRANCISCO, California (GLOBE NEWSWIRE)—Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced positive results from a Phase 1 clinical trial of CB…  

Jun 24 2015

Open Monoclonal Technology Announces OmniAb Alliance with Amgen

PALO ALTO, California—Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Amgen Inc. with access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ human…  

Jun 15 2015

US Food and Drug Administration Accepts Biologics License Application for Anthim (Obiltoxaximab)

PINE BROOK, New Jersey– Elusys Therapeutics, Inc. (Elusys) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and review its Biologics…  

Jun 03 2015